Cancer

CAMBRIDGE, Mass., Mar 30, 2009 (GlobeNewswire via COMTEX) ----Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced the initiation of a Phase 2 clinical trial of IPI-504 (retaspimycin hydrochloride), its lead heat shock protein 90 (Hsp90) inhibitor, in combination with Herceptin(r) (trastuzumab) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Three-Drug Regimen May Preserve the Voice Box in Larynx CancerInduction chemotherapy with a combination of three drugs significantly improved preservation of the larynx in patients with larynx and hypopharynx cancers compared to a commonly used two-drug regimen, French researchers reported.